secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2022-06-23T23:59:59+00:00
Accession:  0001104659-22-073889
Event type: litigation
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex settles Kolltan merger litigation; replaces up to $172.5M milestones with up to $82.5M in payments
--------------------------------------------------------------------------------

- Celldex to pay $15M cash upon signing formal settlement agreement; trial set for June 21, 2022 vacated.
- Additional $15M due upon successful completion of Phase 2 trial of CDX-0159 (barzolvolimab), net of $2.5M credit.
- Additional $52.5M upon first US FDA or EMA regulatory approval of a surviving company product.
- New payments replace prior contingent milestones of up to $172.5M under the 2016 Merger Agreement; broad mutual releases.
- Celldex maintains guidance; cash expected to fund operations through 2025 after paying the $15M initial payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465922073889/0001104659-22-073889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465922073889/tm2219126d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-073889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer